Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

被引:64
作者
Cohen, MB
Giannella, RA
Bean, J
Taylor, DN
Parker, S
Hoeper, A
Wowk, S
Hawkins, J
Kochi, SK
Schiff, G
Killeen, KP
机构
[1] Childrens Hosp, Med Ctr, Div Pediat Gastroenterol Hepatol & Nutr, MLC 2010, Cincinnati, OH 45229 USA
[2] Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH 45229 USA
[3] Childrens Hosp, Med Ctr, Gamble Program Clin Studies, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] VA Med Ctr, Cincinnati, OH USA
[6] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA
[7] AVANT Immunotherapeut Inc, Needham, MA USA
关键词
D O I
10.1128/IAI.70.4.1965-1970.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 x 10(8) CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 10(5) CFU of virulent V cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (greater than or equal to3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P < 0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.
引用
收藏
页码:1965 / 1970
页数:6
相关论文
共 17 条
[1]  
BENENSON AS, 1968, B WORLD HEALTH ORGAN, V38, P277
[2]  
Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P389
[3]   ABO BLOOD-GROUPS AND CHOLERA - NEW OBSERVATIONS ON SPECIFICITY OF RISK AND MODIFICATION OF VACCINE EFFICACY [J].
CLEMENS, JD ;
SACK, DA ;
HARRIS, JR ;
CHAKRABORTY, J ;
KHAN, MR ;
HUDA, S ;
AHMED, F ;
GOMES, J ;
RAO, MR ;
SVENNERHOLM, AM ;
HOLMGREN, J .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (04) :770-773
[4]   MAGNITUDE, KINETICS, AND DURATION OF VIBRIOCIDAL ANTIBODY-RESPONSES IN NORTH AMERICANS AFTER INGESTION OF VIBRIO-CHOLERAE [J].
CLEMENTS, ML ;
LEVINE, MM ;
YOUNG, CR ;
BLACK, RE ;
LIM, YL ;
ROBINSBROWNE, RM ;
CRAIG, JP .
JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (04) :465-473
[5]   PREDISPOSITION FOR CHOLERA OF INDIVIDUALS WITH O-BLOOD GROUP - POSSIBLE EVOLUTIONARY SIGNIFICANCE [J].
GLASS, RI ;
HOLMGREN, J ;
HALEY, CE ;
KHAN, MR ;
SVENNERHOLM, AM ;
STOLL, BJ ;
HOSSAIN, KMB ;
BLACK, RE ;
YUNUS, M ;
BARUA, D .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 121 (06) :791-796
[6]  
GRAVES P, 2001, COCHRANE LIB
[7]   TEMPORAL AND SPATIAL VARIATIONS IN SEDIMENT CHARACTERISTICS ON THE MISSISSIPPI-ALABAMA CONTINENTAL-SHELF [J].
KENNICUTT, MC ;
SCHROEDER, WW ;
BROOKS, JM .
CONTINENTAL SHELF RESEARCH, 1995, 15 (01) :1-18
[8]   DURATION OF SERUM ANTITOXIN RESPONSE FOLLOWING VIBRIO-CHOLERAE INFECTION IN NORTH AMERICANS - RELEVANCE FOR SEROEPIDEMIOLOGY [J].
LEVINE, MM ;
YOUNG, CR ;
HUGHES, TP ;
ODONNELL, S ;
BLACK, RE ;
CLEMENTS, ML ;
ROBINSBROWNE, R ;
LIM, YL .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1981, 114 (03) :348-354
[9]   ENZYME-LINKED IMMUNOSORBENT-ASSAY TO MEASURE ANTIBODIES TO PURIFIED HEAT-LABILE ENTEROTOXINS FROM HUMAN AND PORCINE STRAINS OF ESCHERICHIA-COLI AND TO CHOLERA-TOXIN - APPLICATION IN SERODIAGNOSIS AND SEROEPIDEMIOLOGY [J].
LEVINE, MM ;
YOUNG, CR ;
BLACK, RE ;
TAKEDA, Y ;
FINKELSTEIN, RA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 21 (02) :174-179
[10]   SELECTIVE VS NONSELECTIVE MEDIA AND DIRECT PLATING VS ENRICHMENT TECHNIQUE IN ISOLATION OF VIBRIO-CHOLERAE - RECOMMENDATIONS FOR CLINICAL LABORATORIES [J].
RENNELS, MB ;
LEVINE, MM ;
DAYA, V ;
ANGLE, P ;
YOUNG, C .
JOURNAL OF INFECTIOUS DISEASES, 1980, 142 (03) :328-331